Abstract
In June, results of a large phase III trial with the antiangiogenesis drug Avastin (bevacizumab) showed that patients with metastatic colorectal cancer taking the drug with standard chemotherapy lived 4 months longer than those taking chemotherapy alone. And in August, a phase II study demonstrated that patients with metastatic renal cancer who took Avastin had a greater time to tumor progression than those taking a placebo, although there was no difference in survival time between the two groups.